Comparative Pharmacology
Head-to-head clinical analysis: EPSOLAY versus SARISOL NO 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPSOLAY versus SARISOL NO 2.
EPSOLAY vs SARISOL NO. 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EPSOLAY (ivermectin) is an antiparasitic agent derived from avermectins. It acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions and hyperpolarization of the cell, resulting in paralysis and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). Ivermectin does not readily cross the blood-brain barrier in humans and has minimal affinity for mammalian ligand-gated chloride channels.
SARISOL NO. 2 contains butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing pain and fever. Caffeine is a CNS stimulant that antagonizes adenosine receptors.
Topical: Apply a pea-sized amount to the entire face once daily in the morning. Deliver 1-2 pumps to palm and apply to clean, dry face.
Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg per tablet; 1 to 2 tablets orally every 4 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2 to 4 minutes following intravenous administration; clinically, this rapid clearance limits systemic exposure and allows for localized effect.
Terminal elimination half-life is 12-15 hours; prolonged in hepatic impairment.
Primarily renal excretion of unchanged drug (approximately 60-70% of the absorbed dose) with hepatic metabolism accounting for the remainder; fecal excretion is minimal.
Renal excretion of unchanged drug and metabolites; 70% renal, 30% biliary/fecal.
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent